Patients with the somatic rs121434569 CT genotype (i.e. carrying one copy of the somatic T790M mutation) in combination with an activating EGFR mutation (e.g. L858R or exon 19 deletion) may have increased likelihood of acquired resistance to erlotinib compared to patients with CC genotype. Other genetic and clinical factors may also affect response to erlotinib.